Wendimagegn Alemayehu

Hypofractionated versus conventionally fractionated radiotherapy for patients with localised prostate cancer (HYPRO): final efficacy results from a randomised, multicentre, open-label, phase 3 trial

Luca Incrocci, Ruud C. Wortel, Wendimagegn Alemayehu et al. · The Lancet Oncology · 2016 · 463 citations

Urology, Surgical Oncology, Final Efficacy Results +7

Hypofractionated versus conventionally fractionated radiotherapy for patients with prostate cancer (HYPRO): late toxicity results from a randomised, non-inferiority, phase 3 trial

Shafak Aluwini, Floris J. Pos, Erik C. Schimmel et al. · The Lancet Oncology · 2016 · 308 citations · Full text

Radiation Medicine, Radiation Therapy, Medicine +8

Hypofractionated versus conventionally fractionated radiotherapy for patients with prostate cancer (HYPRO): acute toxicity results from a randomised non-inferiority phase 3 trial

Shafak Aluwini, Floris J. Pos, Erik C. Schimmel et al. · The Lancet Oncology · 2015 · 179 citations · Full text

Radiation Medicine, Health Sciences, Radiation Therapy +7

Reduction of dietary sodium to less than 100 mmol in heart failure (SODIUM-HF): an international, open-label, randomised, controlled trial

Justin A. Ezekowitz, Eloisa Colin-Ramírez, Heather J. Ross et al. · The Lancet · 2022 · 159 citations

Nutrition, Heart Failure, Dietary Sodium +8

Genome-wide association study (GWAS)-identified disease risk alleles do not compromise human longevity

Marian Beekman, Christa Nederstigt, H. Eka D. Suchiman et al. · Proceedings of the National Academy of Sciences · 2010 · 152 citations · Full text

Lifespan Extension, Genome-wide Association Study, Genetic Determinant +15